Table 2.
Multivariable regression analysis
| Factors | N | OR/HR (95% CI) | P-value | Overall P-value |
|---|---|---|---|---|
| Overall survival | ||||
| Conditioning regimen | ||||
| RIC/NMA | 188 | 1.00 (Reference) | < 0.0001 | |
| MAC | 78 | 2.18 (1.53– 3.09) | < 0.0001 | |
| Age | ||||
| ≤ 60 | 142 | 1.00 (Reference) | 0.0053 | |
| > 60 | 122 | 1.61 (1.15– 2.24) | 0.0053 | |
| KPS | ||||
| ≥ 90% | 153 | 1.00 (Reference) | 0.0272 | |
| < 90% | 101 | 1.53 (1.12– 2.08) | 0.0073 | |
| Not reported | 12 | 1.23 (0.60– 2.54) | 0.573 | |
| Disease-free survival | ||||
| Conditioning regimen | ||||
| RIC/NMA | 77 | 1.00 (Reference) | 0.0004 | |
| MAC | 187 | 1.86 (1.32–2.61) | 0.0004 | |
| Age | ||||
| ≤ 60 | 142 | 1.00 Reference) | 0.0337 | |
| > 60 | 122 | 1.41 (1.03– 1.93) | 0.0337 | |
| KPS | ||||
| ≥ 90% | 152 | 1.00 (Reference) | 0.0075 | |
| < 90% | 101 | 1.51 (1.12– 2.05) | 0.0075 | |
| Not reported 4 | 11 | 1.13 (0.53–2.44) | 0.7507 | |
| In vivo T-cell depletion | ||||
| No | 215 | 1.00 (Reference) | 0.0253 | |
| Yes | 49 | 1.50 (1.05–2.13) | 0.0253 | |
| Treatment-related mortality | ||||
| Conditioning regimen | ||||
| RIC/NMA | 187 | 1.00 (Reference) | < 0.0001 | |
| MAC | 77 | 3.31 (2.01–5.45) | < 0.0001 | |
| Age | ||||
| ≤ 60 | 142 | 1.0 (Reference) | 0.0108 | |
| > 60 | 122 | 1.87 (1.16– 3.04) | 0.0108 | |
| KPS | ||||
| ≥ 90% | 152 | 1.00 (Reference) | 0.0142 | |
| < 90% | 101 | 1.98 (1.25– 3.14) | 0.0036 | |
| Not reported | 11 | 1.18 (0.36–3.83) | 0.7811 | |
| In vivo T-cell depletion | ||||
| No | 215 | 1.00 (Reference) | 0.0263 | |
| Yes | 49 | 1.79 (1.07–2.98) | 0.0263 | |
| Acute GVHD | ||||
| Conditioning regimen | ||||
| RIC/NMA | 172 | 1.00 (Reference) | 0.0011 | |
| MAC | 75 | 2.94 (1.54– 5.62) | 0.0011 | |
| GVHD prophylaxis | ||||
| CNI + MMF | 65 | 1.00 (Reference) | 0.0093 | |
| CNI + MTX | 114 | 0.56 (0.28–1.14) | 0.1077 | |
| CNI + others (except MMF, MTX, PTCy) | 18 | 0.36 (0.11–1.17) | 0.0902 | |
| PTCy ± others | 33 | 0.26 (0.10–0.71) | 0.0082 | |
| Other prophylaxis | 17 | 2.17 (0.71– 6.60) | 0.174 | |
| Chronic GVHD | ||||
| GVHD prophylaxis | ||||
| CNI + MMF ± others (except PTCy) | 67 | 1.00 (Reference) | 0.0015 | |
| CNI + MTX ± others (except MMF, PTCy) | 121 | 1.06 (0.68– 1.65) | 0.8045 | |
| CNI + others (except MMF, MTX, PTCy) | 20 | 2.35 (1.31– 4.20) | 0.0041 | |
| PTCy ± others | 37 | 0.44 (0.19– 1.05) | 0.0645 | |
| Other prophylaxis | 17 | 0.65 (0.25– 1.66) | 0.3677 | |
| Year of transplant | ||||
| 2008–2011 | 50 | 1.00 (Reference) | 0.0216 | |
| 2012–2015 | 110 | 0.62 (0.39–0.97) | 0.0382 | |
| 2016–2018 | 102 | 0.48 (0.28–0.82) | 0.0069 | |
| Relapse | ||||
| Disease status at HCT | ||||
| CR | 149 | 1.00 (Reference) | 0.0486 | |
| PR | 80 | 1.40 (0.91–2.17) | 0.1257 | |
| No response/ SD/ PD | 31 | 2.13 (1.23–3.71) | 0.0072 | |
| Not reported | 6 | 0.94 (0.23– 3.87) | 0.932 | |
Abbreviations: CNI, calcineurin inhibitor; CR, complete remission; GVHD, graft-versus-host disease; HCT, hematopoietic cell transplantation; HR, hazard ratio; KPS, Karnofsky Performance Status; MAC, myeloablative conditioning; MMF, mycophenolate mofetil; MTX, methotrexate; OR, odds ratio; PD, progressive disease; PR, partial remission; PTCy, post-transplant cyclophosphamide; RIC/NMA, reduced-intensity conditioning/nonmyeloablative conditioning; SD, stable disease;